⇄ 

Übersetzung für 'T2DM' von Englisch nach Deutsch

type 2 diabetes mellitus <T2DM>

Typ-2-Diabetes mellitus {m} <T2DM>med.

---

pre-type 2 diabetes (mellitus) <pT2D, pre-T2DM>

Prä-Typ-2-Diabetes (mellitus) {m}med.

• Typ-2-Diabetes mellitus {m} <T2DM> = type 2 diabetes mellitus <T2DM>

• Serum FGF21 levels are significantly increased in obesity and in patients with type 2 diabetes mellitus (T2DM), presumably indicating a state of FGF21-resistance.
• The T94A mutant has also been associated with metabolic syndrome conditions, cardiovascular disease and T2DM.
• The Nile rat has gained traction as a useful nutritional model to study Type 2 Diabetes (T2DM).
• The level of expression of NLRP3 inflammasome and caspase-1 has a direct relation to the severity of several metabolic syndromes, such as obesity and type II diabetic mellitus (T2DM).
• But adiponectin, an anti-inflammatory adipokine, which is found in lower concentration in obese and diabetic individuals has shown to be beneficial and protective in type 2 diabetes mellitus (T2DM).

• GSK-3 inhibitors have also shown promise in the treatment of T2DM.
• In T2DM patients Nesfatin-1 is elevated and this could possibly be as a result of a resistance.
• The idea that resistin links obesity to T2DM is now under even more scrutiny, as recent investigations have confirmed ubiquitous expression of resistin in many tissues, rather than those only characteristic of obesity, such as adipocytes.
• Interactions are important for SGLT2 inhibitors because most T2DM patients are taking many other medications.
• Type 2 diabetes mellitus (T2DM) has many variations and factors that influence how it affects the body.

• Consumption of high fructose and sucrose-containing diets have been previously associated with increased risk of T2DM through animal studies linking increased sugar consumption to decreased insulin sensitivity.
• gov registration number: NCT02831361), to evaluate the efficacy and safety of gemigliptin-rosuvastatin fixed-dose combination in patients with T2DM and dyslipidemia in phase III clinical trials (ClinicalTrials.gov registration number: NCT02126358), and to evaluate the efficacy and safety of gemigliptin compared with vildagliptin in Russian patients with T2DM (ClinicalTrials.gov registration number: NCT02343926).
• After SHED injection into Goto-Kakizaki rats, type II diabetes mellitus (T2DM) was ameliorated, suggesting the potential for SHED in T2DM therapies.